LLY

Equity

Eli Lilly and Company

Health Care · Drug Manufacturers - General

$1,051.99

+1,051.99 (+0.00%)

Open

N/A

Day Range

$1,017.43 - $1,052.77

52W Range

$623.78 - $1,133.95

Volume

2M

Price History

Key Statistics

Market Cap

N/A

P/E Ratio

N/A

EPS

N/A

Dividend Yield

N/A

P/B Ratio

N/A

Payout Ratio

N/A

ROE

N/A

Debt/Equity

N/A

Latest News

Sector Update: Health Care Stocks Advance Late Afternoon

MT Newswires 2 hours ago

Sector Update: Health Care Stocks Higher Friday Afternoon

MT Newswires 4 hours ago

Watch: Why Eli Lilly Is Winning the Weight-Loss War

The Wall Street Journal 4 hours ago

Analyst Report: Elanco Animal Health Inc

Argus Research 5 hours ago

Eli Lilly, Incyte Say They Get EMA Panel's Positive Opinion for Olumiant to Treat Severe Alopecia Areata

MT Newswires 9 hours ago

Peers in Health Care

Symbol Name Price Mkt Cap Div Yield Change
001540.KQ AHN-GOOK PHA $8,070.00 N/A 5.45% +0.00%
ABT Abbott Laboratories $116.33 N/A 2.06% +0.00%
NVO Novo Nordisk A/S $37.41 N/A 4.50% +0.00%
EJG.F EBOS Group Ltd. R $11.70 N/A 5.14% +0.00%
5889.T JAPAN EYEWEAR HOLDINGS CO LTD $1,998.00 N/A 4.20% +0.00%
0332.KL TOPVISN $0.17 N/A 11.76% +0.00%
CUV.AX CLINUVEL FPO [CUV] $10.01 N/A 0.50% +0.00%
ABBV AbbVie Inc. $230.81 N/A 2.88% +0.00%

Community Sentiment

Sign in to vote

0% Bullish 0% Neutral 100% Bearish

0 votes

Discussion (0)

Sign in to join the discussion

Loading comments...

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, such as Cyramza for the second-line treatment of gastric cancer or gastro-esophageal junction adenocarcinoma; Erbitux for colorectal cancers and head and neck cancers; Inluriyo for breast cancer; Jaypirca for chronic lymphocytic leukemia or small lymphocytic lymphoma; Retevmo for the treatment of metastatic NSCLC; TYVYT for classic hodgkin's lymphoma; and Verzenio for breast cancer. In addition, the company offers immunology products, which include Ebglyss for severe atopic dermatitis; Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Omvoh for ulcerative colitis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. Further, it provides Emgality for migraine prevention and episodic cluster headache, as well as Kisubla for symptomatic Alzheimer's disease. The company has collaborations with Boehringer Ingelheim Pharmaceuticals, Inc. for the Jardiance product family; and F. Hoffmann-La Roche Ltd and Genentech, Inc. for lebrikizumab, as well as license agreements with Almirall, S.A. for Ebglyss; and Chugai Pharmaceutical Co., Ltd for orforglipron. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.

www.lilly.com →

Dividend Safety

Assessment based on payout ratio, debt levels, profit margins, and dividend growth track record.

60

Safe

Based on 4 fundamental factors

+ 9 years of growth

Analysis Tools

Sign in for analysis tools

Share